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Abstract
Rationale: The chemokine interleukin-8 is implicated in the development of
bronchopulmonary dysplasia in preterm infants. The 77-amino acid isoform of
interleukin-8 (interleukin-877) is a less potent chemoattractant than other shorter
isoforms. Although interleukin-877 is abundant in the preterm circulation, its
regulation in the preterm lung is unknown.
Objectives: To study expression and processing of pulmonary interleukin-877 in
preterm infants who did and did not develop bronchopulmonary dysplasia.
Methods: Total interleukin-8 and interleukin-877 were measured in bronchoalveolar
lavage fluid from preterm infants by immunoassay. Neutrophil serine proteases
were used to assess processing. Neutrophil chemotaxis assays and degranulation
of neutrophil matrix metalloproteinase-9 were used to assess interleukin-8 function.
Main Results: Peak total interleukin-8 and interleukin-877 concentrations were
increased in infants who developed bronchopulmonary dysplasia compared to
those who did not. Shorter forms of interleukin-8 predominated in the preterm lung
(96.3% No-bronchopulmonary dysplasia vs 97.1% bronchopulmonary dysplasia,
p.0.05). Preterm bronchoalveolar lavage fluid significantly converted exogenously
added interleukin-877 to shorter isoforms (p,0.001). Conversion was greater in
bronchopulmonary dysplasia infants (p,0.05). This conversion was inhibited by a-1
antitrypsin and antithrombin III (p,0.01). Purified neutrophil serine proteases
OPEN ACCESS
Citation: Chakraborty M, McGreal EP, Williams A,
Davies PL, Powell W, et al. (2014) Role of Serine
Proteases in the Regulation of Interleukin-877
during the Development of Bronchopulmonary
Dysplasia in Preterm Ventilated Infants. PLoS
ONE 9(12): e114524. doi:10.1371/journal.pone.
0114524
Editor: Oliver Eickelberg, Helmholtz Zentrum
Mu¨nchen/Ludwig-Maximilians-University Munich,
Germany
Received: March 14, 2014
Accepted: November 11, 2014
Published: December 4, 2014
Copyright:  2014 Chakraborty et al. This is an
open-access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its Supporting Information files.
Funding: This work was supported by Sparks, The
Children’s Medical Research Charity (http://www.
sparks.org.uk/) and by Arriva Pharmaceuticals. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: This study was funded in
part by Arriva Pharmaceuticals. This does not alter
the authors’ adherence to PLOS ONE policies on
sharing data and materials.
PLOS ONE | DOI:10.1371/journal.pone.0114524 December 4, 2014 1 / 22
efficiently converted interleukin-877 to shorter isoforms in a time- and dose-
dependent fashion; shorter interleukin-8 isoforms were primarily responsible for
neutrophil chemotaxis (p,0.001). Conversion by proteinase-3 resulted in
significantly increased interleukin-8 activity in vitro (p,0.01).
Conclusions: Shorter, potent, isoforms interleukin-8 predominate in the preterm
lung, and are increased in infants developing bronchopulmonary dysplasia, due to
conversion of interleukin-877 by neutrophil serine proteases and thrombin.
Processing of interleukin-8 provides an attractive therapeutic target to prevent
development of bronchopulmonary dysplasia.
Introduction
Persistent lung inflammation, in the form of a poorly resolved neutrophilia, is
implicated in the pathogenesis of bronchopulmonary dysplasia (BPD) [1], which
is a common disease of preterm infants [2, 3]. Interleukin-8 (IL-8) is a key
mediator of lung inflammation in preterm infants [4], attracting polymorpho-
nuclear leucocyte (PMN) to the lungs [1].
IL-8 (CXCL-8) is an early response chemokine, which is a key chemoattractant
for PMNs to sites of inflammation. It is synthesised by a variety of cells including
alveolar macrophages, endothelial cells, epithelial cells, fibroblasts etc. on
induction by inflammatory stimuli. In-vitro, IL-8 seems to be the dominant CXC
chemokine [5] produced by alveolar macrophages and accounts for most of the
chemotactic activity on PMNs [6]. It has consistently been detected in increased
concentration from epithelial lining fluid in lungs of ventilated preterm infants
who later develop BPD [4, 7], and has been observed to increase before the peak of
inflammatory cell influx [8]. High levels of IL-8 in lung at birth correlate well with
increased duration of ventilation in small preterm infants [9]. Results from
observational studies on IL-8 in the lungs of preterm infants suggests a key role in
persistent neutrophil-driven inflammation, and consequent lung injury, observed
in infants developing BPD [10].
IL-8, a member of the CXC [5] family of chemokines, is expressed by a wide
variety of cells [11]. Due to variations in the number of amino-acids (aa) at the
amino-terminal, several isoforms of IL-8 have been described [12, 13, 14], with the
72 aa isoform (IL-872) being the best characterised. IL-872 is expressed mainly by
immune cells [15, 16] while the 77-aa protein, IL-877, is the major isoform
expressed by non-immune cells [17, 18]. Functionally, IL-872 and other shorter
isoforms are more potent than IL-877 in vitro [19, 20, 21, 22] and in vivo [23, 24].
Several enzymes can convert IL-877 to shorter isoforms including a-thrombin
[19], plasmin [25], matrix metalloprotease-9 (MMP-9) [26] and proteinase-3
(PR3) [27], resulting in significantly increased functional potency [19, 25, 26].
Recently, we reported predominance of IL-877 in the preterm circulation [28].
While total IL-8 has been measured in preterm lungs [29], the concentration of
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IL-877 or its contribution to the total IL-8 pool is unknown. As significant
pulmonary inflammation is observed in infants who develop BPD, we
hypothesised that concentration of the potent shorter isoforms of IL-8 would
predominate in the preterm lung. Our specific aims were to (a) measure
concentration of IL-877 in bronchoalveolar lavage fluid (BALF) of preterm
ventilated infants, (b) understand mechanisms of production and post-
translational modification of IL-877 in the preterm lungs, and (c) compare
differences between infants who develop BPD and those who do not. Our results
suggest PR3 and thrombin are key regulators of IL-877 in BALF from preterm
ventilated infants developing BPD.
Materials and Methods
(Additional details are provided in File S1)
Patient Groups and sample collection
Recruitment of ventilated preterm infants born before 32 weeks gestation,
collection and processing of BALF has been previously described [30, 31]. Infants
were categorised as: BPD group who required respiratory support or supplemental
oxygen (moderate to severe BPD [32]) and No-BPD group who were nursed in
air, both at 36 weeks post-conceptional age. Cord blood from term infants,
delivered by elective caesarean section, and peripheral venous blood from healthy
adult volunteers were collected and processed as described previously [33]. Ethical
approval was obtained from the Research Ethics Committee, Cardiff & Vale
University Health Board, Cardiff, UK, and prior written informed consent was
obtained from parents and healthy adult volunteers.
ELISAs
Commercial ELISAs were used to measure chemokines (except IL-877) and matrix
metalloproteinase-9 (MMP-9) according to the manufacturer’s instructions.
Concentration of IL-877 was measured as previously described [34], except
samples were detected by the detection-antibody from the commercial IL-8 ELISA
described above. Lower limit of sensitivity of the assay was 3.125 pg/ml (Figure S2
in File S1).
PR3 antigen was measured in preterm BALF with an in-house ELISA using a
mouse monoclonal anti-PR3 antibody (File S1).
Conversion of IL-877 by BALF
Exogenously added recombinant human (rh) IL-877 was incubated overnight with
buffer, BALF or BALF with protease inhibitors. Samples were collected at 0 hour
and 18 hours and stored at -80 C˚ until further analysis.
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Airway Epithelial Cell Culture and Stimulation
Cells were obtained from European Collection of Cell Cultures (ECACC) and
grown in 75 cm3 flasks (Corning Life Sciences, Amsterdam, The Netherlands)
containing DMEM media with L-glutamine for A549 cells or F12-K media with L-
glutamine for BEAS-2B cells (both media from HyClone, Cramlington, UK) and
5% heat-inactivated (HI) foetal calf serum (FCS, Sigma-Aldrich Company Ltd.,
Gillingham, UK), incubated in a humidified incubator at 37 C˚ and 5% CO2. Cells
were allowed to grow to 80-90% confluence in a monolayer before being sub-
cultured, using 0.25% Trypsin EDTA (Lonza, Slough, UK). Cell viability was
checked by 0.4% Trypan Blue exclusion (Thermo Scientific, Loughborough, UK).
Human small airway epithelial cells (SAEC, Lonza CC-2547, Slough, UK) were
cultured in 25 cm2 flasks (Corning Life Sciences, Amsterdam, The Netherlands) in
SAEC basal media containing growth supplements (Clonetics SAGM BulletKit
CC-3118) according to Lonza’s guidelines.
Epithelial cells were seeded into 6-well plates at a density of 36105 cells/ml and
allowed to adhere for more than 12 hours prior to washing with saline and further
culture in serum-free media (A549 and BEAS-2B) for six hours (SAECs were
grown in defined serum-free medium). Cells were washed again in saline prior to
stimulation with IL-1b (5 ng/ml for A549 and BEAS-2B cells and 1 ng/ml for
SAEC) in duplicate for 18 hours at 37 C˚ and 5% CO2; supernatants were collected
after incubation and immediately frozen at 280 C˚ until further analysis.
PMN and monocyte purification and stimulation
PMNs and mononuclear cells from term cord blood and from healthy adult
human volunteers were cultured in RPMI 1640 medium with 10% heat-
inactivated foetal calf serum and stimulated with lipopolysaccharide (LPS) in
duplicate for 18 hours at 37 C˚ and 5% CO2. Supernatants were stored at 280 C˚
until further analysis.
Conversion of IL-877 by purified proteases
Purified human neutrophil elastase (NE), cathepsin-G (CG) and PR3 were
incubated with rhIL-877 at 37 C˚ in buffer. Samples were collected at specified
time-points from 0 min to 24 hours and the reaction was immediately stopped by
adding alpha-1 antitrypsin (AAT); samples were stored at -80 C˚ until further
analysis by ELISA.
Neutrophil Degranulation Assay
Purified PMNs from healthy adult human volunteers were exposed to
cytochalasin B for 15 minutes before stimulation by N-Formyl-Met-Leu-Phe
(fMLP), rhIL-872 or rhIL-877 controls at 10 nM each, or samples collected from
conversion experiments with purified proteases. After incubation for 30 min at
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37 C˚, samples were centrifuged at 200 g for 2 min and supernatants stored at -
80 C˚ until further analysis.
Neutrophil Chemotaxis Assay
Chemotaxis of isolated human neutrophils (26105 per well) was measured in
response to infant BALF, with or without 10 mg/ml of anti-total human IL-8
neutralising antibody or anti-human IL-877 neutralising antibody. Migrated cells
were counted (cells/ml) with a haemocytometer after 60 min incubation.
Thrombin activity assay
Thrombin activity in preterm BALF was measured using a specific substrate S2238
(total activity). Background activity was measured by inhibiting the activity with
hirudin and specific activity was calculated after subtracting background from
total activity.
Statistical Analysis
Statistical analysis was performed on GraphPad Prism version 5.03 for Windows
(GraphPad Software, San Diego, CA, USA). Non-normally distributed clinical
data are reported as medians and inter-quartile range (IQR); data from all other
experiments, which were normally distributed, are reported as means and
standard error of mean (SEM). Data from BALF incubations and time-course
experiments with IL-877 and purified proteases are expressed as relative fold
change from 0 hour. Comparison of data between two groups was performed by
Mann-Whitney U test (clinical data) and two-tailed unpaired t-test (all other
data). Data between multiple groups was compared by one-way ANOVA with
post-hoc multiple-comparison tests as appropriate (details mentioned in figure
legends). Data from time-course and dose-response experiments were compared
by two-way ANOVA with Bonferroni correction. Categorical data was compared
by using Fisher’s exact test. Correlations were assessed by using Spearman’s rank
correlation test. p,0.05 was considered significant.
Results
Clinical Data
Clinical characteristics of the two groups are shown in table 1. Thirty-eight
samples were analysed from 22 infants (11 No-BPD and 11 BPD). The number of
ventilation-days (p50.004) and peak fractional oxygen requirement (FiO2;
p50.002) were significantly higher in the BPD infants but all other characteristics
were similar between the two groups.
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Expression of IL-8 isoforms and chemokines
IL-8 was detected in all 38 samples but IL-877 was below the detection limit in
three BPD and two No-BPD samples. Peak total IL-8 concentration (median No-
BPD 3401 pg/ml, inter-quartile range 1587–19080 pg/ml vs BPD 175600 pg/ml,
7064–202700 pg/ml; p50.01, Figure 1a) and corresponding IL-877 (No-BPD
144.3 pg/ml, 83.6–552.6 pg/ml vs BPD 2753 pg/ml, 140.1–5668 pg/ml; p50.03,
Figure 1b) concentration in BALF were significantly higher in the BPD infants
compared to No-BPD infants. However, IL-877 was a minor proportion of the
total IL-8 in all of the samples, and there was no significant difference between the
two groups (IL-877 in No-BPD median 2.9%, 1.3–5.3% vs BPD 2.3%, 1.5–3.0%;
p50.39, Figure 1c); significant correlation was observed between total IL-8
expression and corresponding IL-877 concentration in preterm BALF (n522,
Spearman r50.94, p,0.0001; Figure S3 in File S1). Thus, concentration of the
shorter isoforms of IL-8 predominated in BALF from preterm ventilated infants.
The majority of IL-8 in preterm circulation is reported to be IL-877, in contrast
to term infants or adult circulation [28]. However, no significant correlation was
observed between gestation and IL-877 concentration (n513, r520.47, p50.1;
Figure S4a in File S1) or the proportion (percentage) of IL-877 (n513, r520.14,
p50.65; Figure S4b in File S1) in preterm BALF. Only samples from day 1 of life
were included in this analysis to reflect in-utero concentration.
No significant correlation was found between the peak inspiratory pressure
(PIP) or peak fractional oxygen requirement (FiO2) with IL-8 expression in either
of the two groups of infants. When all infants are analysed together, there was
moderate correlation between PIP and IL-8 expression in BALF (r50.6, p50.01).
Table 1. Patient and clinical characteristics.
No-BPD BPD (moderate to severe) p
Total infants 11 11
Total samples 13 25
Gestational age (weeks)* 28+3 (27–29+4) 27+5 (25+4–29+2) 0.45
Birth weight (g)* 1120 (960–1250) 905 (798.8–1120) 0.14
Prolonged rupture of membranes (.24 hours)‘ 1 (10) 2 (22) 1.0
Antenatal steroids (>24 hours)‘ 9 (82) 9 (82) 1.0
Caesarean delivery‘ 5 (45) 6 (55) 1.0
Exogenous surfactant replacement‘ 11 (100) 11 (100) 1.0
Mechanical ventilation-days* 1.0 (1.0–1.75) 6.5 (5.0–15.5) 0.004
Peak PIP* 17.0 (15.75–21.5) 22.0 (20.0–25.0) 0.07
Peak FiO2* 21.0 (21.0–30.5) 41.0 (32.5–70.5) 0.002
Patent ductus arteriosus‘ 5 (45) 8 (73) 0.39
Peak C-Reactive Protein (CRP)* 4.0 (1.5–14.5) 18.0 (6.5–82.0) 0.08
Lung Infection (16sRNA)‘ 2 (18) 4 (36) 0.64
*Values shown are medians (inter-quartile range) with superscript numbers indicating days in addition to gestation in weeks; ‘ values shown are numbers of
infants (percentage of total in group).
doi:10.1371/journal.pone.0114524.t001
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Since other chemokines can attract neutrophils by binding the same receptors
as IL-8, we measured peak concentration of growth regulated oncogene-a (GRO-
a, CXCL1), GRO-b (CXCL2) and epithelial neutrophil-activating protein-78
(ENA-78, CXCL5). While GRO-a was significantly increased in the BPD infants
(p,0.05), there were no significant differences in concentration of GRO-b or
ENA-78 between the two groups (figure S1 in File S1).
Figure 1. Expression of IL-8 and IL-877 in preterm BALF. (a) Peak concentration of total IL-8, (b)
corresponding IL-877 and (c) proportion of IL-877, expressed as a percentage of total IL-8, in preterm BALF
from infants in the No-BPD group (circles, n511) and BPD group (squares, n511). Groups are represented on
the x-axis while concentration of each antigen (pg/ml, log scale) or proportion (as a percentage) is
represented on the y-axis. Each point represents a single infant and bars are at medians. (*5p,0.05)
doi:10.1371/journal.pone.0114524.g001
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IL-877 Expression by Cells in vitro
We next looked at expression of IL-877 in two adult lung cell-lines A549 (alveolar
epithelial cells) and BEAS-2B (bronchial epithelial cells) and also in primary adult
small-airway epithelial cells (SAEC), as well as in cord blood PMNs and
monocytes from term infants delivered by elective caesarean section. Although
unstimulated A549 cells expressed negligible IL-8, this increased 29-fold on
stimulation, with 60% of it being IL-877 (Figure 2a and S5a in File S1).
Unstimulated BEAS-2B cells expressed all of their IL-8 as IL-877; on stimulation,
there was an 89-fold increase in expression of total IL-8, of which around 66% was
IL-877 (Figure 2a and S5a in File S1). SAECs expressed 25% of their IL-8 as IL-877
in the absence of any stimulation; this increased to 56% (Figure 2a and S5a in File
S1) on stimulation, which also resulted in a 10-fold increase in expression of total
IL-8. Term cord-blood PMNs expressed approximately 34% of their IL-8 as IL-877
with or without stimulation (Figure 2b and S5b in File S1). Unstimulated and
stimulated cord monocytes expressed 33% and 53% of IL-8 as IL-877 respectively (
Figure 2b and S5c in File S1). These data suggest that a significant proportion of
IL-8 expressed by resident and infiltrating cells in the lungs is the IL-877 form.
Convertase Activity of BALF
We have shown that a minority of the IL-8 in preterm BALF is expressed as the IL-
877 form, although it is the predominant form expressed by stimulated lung cells.
As several proteases are known to convert IL-877 to shorter isoforms
[19, 25, 26, 27], we investigated processing of IL-877 by protease activity of preterm
BALF with appropriate controls (Figure S6 in File S1). On incubating BALF with
exogenously added rhIL-877 (10 ng/ml51.1 nM), recovery of this isoform after an
18 hour incubation was reduced by 30% compared to initial concentration
(p,0.001, Figure 3a). To explore the mechanism of this conversion, a number of
specific inhibitors were used: alpha-1 antitrypsin (AAT) for neutrophil serine
proteases, phenylmethylsulfonyl fluoride (PMSF) for serine proteases, 1-10
phenanthroline for metalloproteases and antithrombin-III (ATIII) for thrombin.
While both AAT (p,0.01) and PMSF (p,0.001) resulted in significant inhibition
of conversion of IL-877 by preterm BALF, no similar inhibition was observed with
1-10 phenanthroline, suggesting neutrophil serine proteases, and not metallo-
proteases, were responsible for this conversion (Figure 3a). The inhibition of
convertase activity by ATIII (p,0.01) suggested that thrombin and other
coagulation proteases were active within the preterm lung. There was significantly
increased convertase activity in BPD infants (leading to decreased recovery of IL-
877) compared to No-BPD (p50.03, Figure 3b). To look at possible differential
effect of proteases in the two groups, we have analysed "protection" from
conversion by AAT, ATIII and PMSF for BPD and No-BPD infants separately.
There were no statistically significant differences for any of the antiproteases
between the two groups; however, protection in the No-BPD group was high
regardless of the anti-protease used while for the BPD group, maximum
protection was achieved by PMSF (has broader anti-protease effect than AAT or
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ATIII individually). AAT provided greater protection than ATIII in the BPD
group.
Conversion of IL-877 by purified neutrophil proteases
Our data suggested that active neutrophil and coagulation cascade serine
proteases in BALF can significantly convert exogenously added IL-877. The role of
thrombin and plasmin has been studied previously [19, 25]. We next proceeded to
study the pattern of this conversion by the three neutrophil serine proteases NE,
CG and PR3 individually. All three proteases showed significant convertase
activity when incubated with rhIL-877, when compared with buffer control at all
time-points (Figure 4a) and varying doses of proteases (Figure S7 in File S1). This
was time-dependent and the majority of this conversion took place by 6 hours
(17% of IL-877 remaining with NE, 2% with CG, 6% with PR3; Figure 4a). Among
the three serine proteases, CG was the most potent; percentage of remaining IL-
877 was significantly lower when compared with NE after 2 hours (p,0.05) and
4 hours (p,0.05) of incubation; and also on comparison with PR3 after 1 hour
Figure 2. Expression of IL-877 from cultured cells. Proportion of IL-877, expressed as a percentage of total
IL-8, from un-stimulated (open bars) and stimulated (shaded bars) (a) airway epithelial cells and (b) term cord-
blood neutrophils and monocytes. Cells-types are represented on the x-axis while percentage of IL-877 is
represented on the y-axis. Bars are means (¡ SEM) of three independent cell-culture experiments, each
conducted in duplicate. All supernatants were separately measured by ELISA in duplicate.
doi:10.1371/journal.pone.0114524.g002
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(p,0.01) and 2 hours (p,0.001) of incubation. The percentage of remaining IL-
877 was not significantly different between NE and PR3 at any time-point. IL-877
was converted to shorter isoforms of IL-8, which were detectable by immunoassay
for total IL-8 (Figure 4b). However, after incubation with proteases for.12 hours,
there was a trend towards further degradation of IL-8 to peptides undetectable by
ELISA. This was most evident with PR3 where total IL-8 detected (38% of starting
concentration) was significantly lower when compared with buffer control (76%
of starting concentration) at 24 hours (p,0.01). Such an effect has been reported
previously with an excess of NE [35] resulting in loss of functional activity.
Figure 3. Convertase activity of preterm BALF. (a) Concentration of IL-877 detected by ELISA at 0 hours
and after incubation in different conditions for 18 hours. Conditions are detailed on the x-axis and fold change
of IL-877 (compared to concentration at ‘‘0-hour’’) on the y-axis. All bars are at means (¡ SEM). Conditions
were compared by repeated measures ANOVA with Dunnets correction, comparing against a control column
(BALF at 18 hour, n518). (b) Concentration of IL-877 detected by ELISA at 18 hours in No-BPD (open bar,
n59) and BPD (shaded bar, n59) infants. Infant groups are detailed on the x-axis and concentration of IL-877
(fold change from ‘‘0-hour’’) on the y-axis. All bars are at means (¡ SEM). (*5p,0.05, **5p,0.01,
***5p,0.001)
doi:10.1371/journal.pone.0114524.g003
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Functional activity of IL-877 after incubation with proteases
We have shown that all three neutrophil serine proteases efficiently convert IL-877
to shorter isoforms over time. Next, we proceeded to test the functional activity of
the converted products in a neutrophil degranulation assay (figure S8 in File S1).
We hypothesised that if IL-877 was converted to functional shorter isoforms, then
it would be reflected in increased functional potency of the products. Although
NE and CG efficiently converted IL-877 (Figure 4a), no significant differences in
functional activity were observed between the products from NE or CG, compared
to buffer-control, at any time-point (Figure S9 in File S1). In contrast, there was a
significant increase in potency in the products after incubation with PR3 (
Figure 5) after 1 and 2 hours (p,0.01 compared to buffer control) and 3 and
4 hours (p,0.05 compared to buffer control). This suggests that although all the
three serine proteases can convert IL-877, only conversion by PR3 results in a
Figure 4. Time-course of conversion of IL-877 by purified proteases. (a) Fold change in concentration of
IL-877 and (b) total IL-8 on incubation with by purified neutrophil proteases at different time-points. Time
(hours) is represented on the x-axis while the fold-change in concentration (compared to concentration at ‘‘0-
hour’’) is represented on the y-axis. Points plotted are means (¡ SEM) of three independent experiments,
each measured by ELISA in duplicate. Differences in concentration was compared by two-way ANOVA with
Bonferroni’s correction. (**5p,0.01; p-values for figure 4a are mentioned in the text)
doi:10.1371/journal.pone.0114524.g004
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significant increase in functional potency suggesting a key regulatory role for this
enzyme towards IL-877 in the preterm lung.
PR3 antigen expression and thrombin activity in preterm BALF
Both peak PR3 antigen expression (p50.03, Figure 6a) and peak thrombin activity
(p50.03, Figure 6b) were significantly higher in BALF from BPD infants
compared to No-BPD infants when measured in an in vitro assay. Thrombin
activity was measured in BALF from a wider cohort of preterm ventilated infants
(same epoch and collected and processed identically), due to limited BALF
availability.
Neutrophil chemotaxis to preterm BALF
To establish the importance of IL-8 as a chemokine in preterm BALF, chemotaxis
of purified adult human neutrophils to pooled BALF from BPD infants was
assessed. Inhibition of total IL-8, but not IL-877, resulted in significant reduction
of neutrophil chemotaxis (figure 7) suggesting that shorter forms of IL-8 were
primarily responsible for the effect.
Discussion
This is the first report of IL-877 expression in the lungs of preterm infants.
Although total IL-8 and IL-877 concentration were significantly increased in
infants who developed BPD, the majority of the IL-8 measured in preterm BALF
seemed to be the more potent shorter isoforms. Resident and infiltrating cells in
the lung express a significant proportion of IL-8 as the 77 aa isoform. We have
Figure 5. Modulation by proteinase-3. Summary of processing of rhIL-877 by purified proteinase-3 showing
recovery of total IL-8 (squares) and IL-877 (circles) and release of MMP-9 from neutrophils in response to the
products of conversion (triangles). Time (hours) is represented on the x-axis while IL-8/MMP-9 (fold change
from 0-hour values) is represented on the y-axis. Points plotted are means (¡ SEM) of three independent
experiments, each measured by ELISA in duplicate. Statistical differences in concentration compared to
buffer-control at each time-point was tested by 2-way ANOVA with Bonferroni’s correction. (*5p,0.05,
**5p,0.01, ***5p,0.001).
doi:10.1371/journal.pone.0114524.g005
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Figure 6. Proteinase-3 antigen and thrombin activity in preterm BALF. Peak (a) proteinase-3 expression
(nM) and (b) thrombin activity (mIU/ml) in BALF from No-BPD (circles, n59 for proteinase-3 antigen and n513
for thrombin activity) and BPD (squares, n58 for proteinase-3 antigen and n513 for thrombin activity) infants.
Groups are represented on the x-axis while concentration of each antigen (nM) or activity (mIU/ml) is
represented on the y-axis. Points plotted are from individual infants and bars are at medians. (*5p,0.05)
Figure 7. Neutrophil chemotaxis to preterm BALF. Chemotaxis of adult human neutrophils to pooled BALF
from BPD infants after incubation for 60 min. Conditions are detailed on the x-axis while concentration of
neutrophils (cells/ml) are expressed on the y-axis. Bars are at means (¡ SEM) of three independent
experiments, each done in triplicate. Conditions were compared by one-way ANOVA with Dunnet’s correction,
comparing against a control column (BALF only). (***5p,0.001).
doi:10.1371/journal.pone.0114524.g007
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demonstrated a significant capacity of neutrophil serine proteases and thrombin
in the preterm BALF to convert IL-877 to its shorter isoforms. Specifically,
conversion by PR3 resulted in shorter isoforms with increased functional activity.
The activity could, however, be inhibited by appropriate anti-proteases.
Persistent, neutrophil-driven inflammation has been strongly implicated in the
pathogenesis of BPD with IL-8 being a key chemokine involved in the process.
Our results are in keeping with previous data that IL-8 concentration is
significantly increased in the lungs of infants developing BPD [4]. Although
mechanical ventilation and oxygen toxicity are known to contribute to lung
inflammation in preterm infants [10], in our cohort, IL-8 expression was not
significantly correlated with PIP or with FiO2 in either of the two groups of
infants when examined individually. IL-877 was detected at lower concentration,
which agrees with our hypothesis that the shorter isoforms constitute the majority
of the IL-8 concentration in preterm BALF, and is in keeping with persistent
neutrophil influx into the lungs. However, this is in contrast to the higher
proportion of circulating IL-877 in preterm infants (.60%) as reported recently
[28]. Two possibilities, to explain the low concentration of IL-877 in preterm
BALF, were reduced expression or post-translational modification. Pulmonary
epithelial cell lines are known to express IL-8 on stimulation [36, 37]; however,
expression of IL-877 has not been described before. We have shown for the first
time that IL-877 constitutes a significant proportion of the total IL-8 secreted by a
variety of airway cell-lines and primary small airway cells, both unstimulated and
on stimulation. Other abundant cell types in the preterm lung include neutrophils
and cells of the monocytes/macrophage lineage. Previously, IL-877 expression has
been reported to range from 17–38% of total IL-8 from adult monocytes [14] and
mixed mononuclear cells [13], and about 60% of total IL-8 from PMNs [27]. We
have described the expression of IL-877 from term neonatal cord-blood PMNs and
monocytes. Our results are in general agreement with adult data published
previously. Taken together, these data suggest that both resident and infiltrating
cells in the lung could express significant quantities of IL-877, especially on
stimulation.
As resident and infiltrating cells in the lungs express significant proportion of
IL-877, the low concentration of IL-877 in the preterm lungs is likely to be due to
post-translational modification. Indeed, BALF from all infants significantly
converted exogenously added IL-877 after 18 hours of incubation, which was more
pronounced in the BPD infants. This was mediated mainly by neutrophil serine
proteases and thrombin. As we have shown previously [38], excess bovine serum
albumin (BSA) has no inhibitory effect on the activity of the neutrophil serine
proteases, leading us to conclude that this is unlikely to be a non-specific
inhibition. AAT itself can bind to IL-8 (substrate sequestration) to reduce its
bioavailability [39], a property which could have influenced our results. We have
demonstrated inhibition of IL-877 cleavage by PMSF, suggesting protease
inhibition is the mechanism resulting in this effect. We believe further studies will
need to be conducted to confirm the precise mechanism in vivo. The role of
proteolytic enzymes in the pathogenesis of BPD is still being debated. Early studies
Pulmonary IL-877 in Preterm Infants
PLOS ONE | DOI:10.1371/journal.pone.0114524 December 4, 2014 14 / 22
in preterm infants have suggested the involvement of neutrophil proteases in
contributing to inflammation and lung injury [40, 41], and several proteases,
including NE and metallo-proteinases [42, 43, 44] have been implicated in the
pathogenesis of BPD. However, data from other studies have been less clear on the
relationship [45]. Experimental and adult data seem to support the hypothesis
that uncontrolled proteases activity can contribute to lung injury [46, 47], as
observed in lung autopsy specimens of infants with BPD [48]. We have recently
shown in the preterm lung that increased expression of these proteases can be
episodic, related to infective episodes, and is associated with the development of
BPD [31]. Apart from the direct effect of proteases, post-translational
modification of chemokines [49] can also influence local immune function and
have an impact on tissue injury. This effect is particularly important for IL-8, as
cleavage by proteases may result in isoforms with enhanced functional activity.
As shown previously, PR3 converts IL-877 to IL-870, but NE and CG were not
involved in the conversion process [27]. We have shown that all three of the main
serine proteases in PMNs can convert IL-877 to shorter isoforms. This is effective
both over time and over a dose range. CG was the most potent and NE the least
potent. Interestingly, with longer incubation periods, there was a decrease in the
amount of total IL-8 recovered, most evident with PR3. This suggests the
existence of several potential cleavage sites for the enzymes on the IL-8 molecule,
which are distal from the NH2-terminal. NE has previously been reported to
abolish IL-8 activity by a similar process [35], although the authors did not find a
similar effect with CG (PR3 was not studied). In our study, all three PMN serine
proteases reduced IL-8 recovery at the concentrations tested. PR3 initially
increased functional potency of IL-877, but over time IL-8 was cleaved into smaller
peptides that were undetectable by ELISA; similar results were obtained on
incubating IL-872 with PR3 (Figure S10 in File S1). Taken together, these results
suggest that PR3 may be a key modulator of IL-8 function in the preterm lungs,
which seems to be a key chemoattractant in preterm BPD BALF (figure 7). This
could have significant implications for lung inflammation leading to BPD, and
further studies need to be conducted to confirm the clinical effects of this
modulation in vivo.
Cross-talk between inflammation and the coagulation cascade has previously
been reported [50, 51]. To our knowledge, only one previous study has reported
thrombin activity in BALF from preterm ventilated infants [52]; surprisingly, they
found lower activity in BPD infants compared to No-BPD infants on days 2 and 4
of life. In a recent in vitro model, activation of the coagulation cascade by BPD-
BALF was shown to promote fibrotic responses [53]. Activation of the clotting
cascade has been shown to contribute to fibrotic lung diseases [54, 55] where
thrombin is part of the final common coagulation pathway. Our analysis suggests
that thrombin is involved in modulating lung inflammation in ventilated preterm
infants by post-translational modification of IL-8, thus attracting increased
numbers of neutrophils into the lungs expressing inflammatory mediators and
serine proteases. Recently, inhibition of neutrophil serine proteases was shown to
improve lung growth in a murine model of BPD [56]. Taken together our data
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suggest that inhibition of specific proteases could regulate IL-8 activity and
modulate pulmonary inflammation in preterm infants at risk of BPD; an in vivo
study would be needed to confirm this hypothesis.
Although IL-8 has consistently been reported at higher concentration in the
lungs of infants developing BPD, there may be other chemokines involved in
neutrophil chemotaxis via stimulation of the IL-8 cognate receptors [57]. The
concentration of BALF GRO-a was significantly higher in BPD infants, but those
of GRO-b and ENA-78 were comparable in the BPD and No-BPD groups,
suggesting that these chemokines may not be as dominant as IL-8 during
neutrophil migration. Furthermore, BALF from BPD infants was highly
chemotactic for neutrophils. This chemotactic response was significantly inhibited
by neutralising total IL-8, but not IL-877, thereby suggesting that the shorter IL-8
isoforms are more potent neutrophil chemoattractants involved in the
pathogenesis of BPD.
IL-877 seems to be the predominant isoform of IL-8 found in the systemic
circulation of preterm infants [28]. Moreover, preterm plasma has significantly
lower convertase activity for IL-877 compared to term or adult plasma [28]. Since
chemotatic potency of IL-877 is significantly lower than IL-872, this unique pattern
of expression of the IL-8 isoforms in the preterm circulation could be designed to
attenuate inflammation in utero. It is possible that IL-877 may have other non-
inflammatory developmental roles in the foetus. However, in a localised
inflammatory milieu like the preterm ventilated lungs, IL-8 seems to have a
predominantly inflammatory role resulting in the persistent influx, and activation,
of neutrophils into the lungs. The low concentration of IL-877 in preterm BALF,
possibly due to conversion into the more potent shorter isoforms, supports this
hypothesis. We speculate that inhibition of this conversion could potentially shift
the balance towards attenuation of lung inflammation and injury. This hypothesis
needs to be tested in vivo.
We acknowledge certain limitations of this study. The airway cell-lines and
primary cells used in our experimental models are all from adult populations and
may not reflect conditions in the preterm lung accurately. The transcriptional
activity of preterm lung cells is not known; however, they are known to be less
mature than term cells [1]. We have also used term cord-blood cells to look at
expression of the chemokine. We believe that the future use of appropriate models
may enable us to overcome some of these difficulties. We have measured PR3
antigen concentration; it is possible that all of it may not be active. We also
acknowledge possible differences in in vitro and in vivo activity, and it is very likely
that the latter is more efficient; this needs to be addressed in future studies. Our
study was undertaken with the aim of defining the extent to which IL-877 was
expressed in the preterm lung given that a previous study reported IL-877 to be the
dominant form of IL-8 in circulation in preterm infants. Having demonstrated
that IL-877 was not dominant in airway lavage fluid, we undertook a series of
experiments to understand why this might be the case. We acknowledge that there
may well be additional mechanisms at play which are beyond the scope of this
study.
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In conclusion, our data show that in the lungs of ventilated preterm infants, the
majority of IL-8 expression seems to be the shorter (more potent) isoforms; this is
also supported by the pattern of cellular infiltration into the lungs. The
concentration of IL-877 is low in preterm BALF, although it has been previously
detected as a considerable proportion of total IL-8 in the preterm circulation. PR3
and thrombin are key modulators of IL-8 in the preterm lung – targeting of
processing of IL-8 provides an attractive therapeutic target to prevent pulmonary
inflammation in infants at risk of developing BPD.
Supporting Information
File S1. Supporting information. Figure S1, Chemokines in preterm BALF. Peak
concentration of (a) CXCL1, (b) CXCL2 and (c) CXCL5 in preterm BALF.
Groups are represented on the x-axis while concentration of chemokines (pg/ml)
are represented on the y-axis. Each point represents peak value from a single
infant and bars are at medians (*5p,0.05). Figure S2, Modification of IL-877
ELISA. Antigens IL-877 (open circles) and IL-872 (open squares) were captured by
(a) N11 and (b) BD capture antibody. Both were detected by the BD detection
antibody. Concentration of the antigens is represented on the x-axis (pg/ml) while
absorbance at 450 nm (corrected at 570 nm) is represented on the y-axis. Points
represent means (¡ SEM) of three independent experiments. Values were
compared by two-way ANOVA with Boferroni’s post-test (***5p,0.001). Figure
S3, Expression of IL-8 and IL-877. Concentration of peak total IL-8 (pg/ml) and
corresponding concentration of IL-877 (pg/ml) are plotted on the x- and y-axis
respectively. Each point represents a single infant and correlation was tested by
calculating Spearman’s coefficient. Figure S4, Gestation and IL-877 expression.
Correlation of gestation at birth with (a) concentration of IL-877 and (b)
percentage of IL-8 expressed as IL-877, in preterm BALF. Birth gestation of infants
(weeks) is plotted on the x-axis while first day IL-877 concentration (pg/ml) or
proportion of total IL-8 (percentage) in preterm BALF is plotted on the y-axis.
Each point represents a single infant and correlation was tested by calculating
Spearman’s coefficient. Figure S5, Expression of IL-877 from cells. Concentration
(pg/ml) of total IL-8 (open bars) and IL-877 (shaded bars) from (a) airway
epithelial cells and term cord-blood (b) PMNs & (c) monocytes, both
unstimulated (U) and when stimulated (S) with IL-1b (airway epithelial cells) or
LPS (cord-blood cells). Cell-lines and incubation conditions are represented on
the x-axis while concentration (pg/ml) is on the y-axis. Bars are at means (¡
SEM) of at least three separate experiments. Figure S6, Panel of controls.
Concentration of IL-877 detected by ELISA at 0 hours and after incubation in
different conditions for 18 hours. Conditions are detailed on the x-axis and
concentration of IL-877 (pg/ml) on the y-axis. Open bars represent buffer
controls, grey bar represent BALF samples at 0 hour and black bar represents
BALF samples after 18 hours incubation (n518). All bars are at means (¡ SEM).
Conditions were compared by one-way ANOVA with Dunnets post-hoc test
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comparing against a control column (BALF at 0 hour) (***5p,0.001). Figure S7,
Protease dose-response. Conversion of IL-877 by purified human neutrophil (a)
elastase, (b) cathepsin-G and (c) proteinase 3 at varying concentration. Ratio of
enzyme: substrate is represented on the x-axis while the fold-change of total IL-8
(circles) and IL-877 (squares) from original concentration is represented on the y-
axis. Points plotted are means (¡ SEM) of three independent experiments.
Concentration of IL-877 is compared to corresponding concentration of total IL-8
by two-way ANOVA with Bonferroni’s post-test (*5p,0.05, **5p,0.01,
***5p,0.001). Figure S8, Establishing the neutrophil degranulation assay. MMP-
9 expressed from neutrophils after degranulation by control conditions (open
bars), rhIL-872 (grey bars) and rhIL-877 (black bars). Details of conditions are
represented on the x-axis while expression of MMP-9 is represented on the y-axis
(expressed as a fold change compared to the positive control). Bars are at means
(¡ SEM) of three independent experiments. Difference in means was compared
by one-way ANOVA with Tukey’s post-test (comparing all pairs of columns). */
*** 5 significant compared to negative control; ## 5 significant compared to
rhIL-872 at a concentration of 10
28 M (*5p,0.05, ***5p,0.001, ##
5p,0.01). Figure S9, Functional activity of IL-8 isoforms. Summary of
processing of rhIL-877 by (a) buffer, (b) purified elastase and, (c) purified
cathepsin G showing concentration of recovered total IL-8 (squares), IL-877
(circles) and MMP-9 from degranulation of neutrophils (triangles) by the
products of conversion. Time (hours) is represented on the x-axis while IL-8/
MMP-9 (fold change from 0-hour values) is represented on the y-axis. Points
plotted are means (¡ SEM) of three independent experiments. Statistical
differences in concentration compared to buffer-control at each time-point was
tested by 2-way ANOVA with Bonferroni’s post-test. (***5p,0.001). Figure S10,
Processing of rhIL-872 by purified proteinase-3. Recovery of total IL-8 (expressed
as a fold change from 0-hour) on incubation with buffer (circles) and proteinase-3
(squares) over 24 hours. Time (hours) is represented on the x-axis while fold-
change in concentration (compared to concentration at ‘‘0-hour’’) is represented
on the y-axis. Points plotted are means (¡ SEM) of three independent
experiments. Differences in concentration was tested by two-way ANOVA with
Bonferroni’s post-test (***5p,0.001).
doi:10.1371/journal.pone.0114524.s001 (DOC)
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